Federal Register / Vol. 65, No. 106 / Thursday, June 1, 2000 / Notices 35107

Time: 12:00 p.m. to 1:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Georgetown Holiday Inn, 2101

Wisconsin Avenue, NW, Washington, DC

20007.

Contact Person: Eileen W. Bradley, DSC,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5120,

MSC 7854, Bethesda, MD 20892, (301) 435–

1179, bradleye@csr.nih.gov

Name of Committee: Oncological Sciences

Integrated Review Group Chemical Pathology

Study Section.

Date: June 14–16, 2000.

Time: 8:30 a.m. to 5:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: Arlington Hyatt, 1325 Wilson

Boulevard, Arlington, VA 22209.

Contact Person: Syed Quadri, PhD,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 4144,

MSC 7804, Bethesda, MD 20892, (301) 435–

1211.

Name of Committee: Integrative,

Functional and Cognitive Neuroscience

Integrated Review Group Visual Sciences B

Study Section.

Date: June 14–15, 2000.

Time: 8:30 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Wyndham City Center, 1143 New

Hampshire Avenue, NW, Washington, DC

20037.

Contact Person: Leonard Jakubczak, PhD,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5172,

MSC 7844, Bethesda, MD 20892, Bethesda,

MD 20892, (301) 435–1247.

Name of Committee: Immunological

Sciences Integrated Review Group

Immunobiology Study Section.

Date: June 14–15, 2000.

Time: 9:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Betty Hayden, PhD,

Scientific Review Administrator, Center for

Scientific, National Institutes of Health, 6701

Rockledge Drive, Room 4206, MSC 7812,

Bethesda, MD 20892, (301) 435–1223.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: June 14–16, 2000.

Time: 7:00 p.m. to 11:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Hampton Inn, North, 2300 Green

Road, Ann Arbor, MI 48105.

Contact Person: Nadarajen A. Vydelingum,

PhD, Scientific Review Administrator,

Special Study Section–8, Center for Scientific

Review, National Institutes of Health, 6701

Rockledge Drive, MSC 7854, Rm 5122,

Bethesda, MD 20892, (301) 435–1176,

vydelinn@csr.nih.gov

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: June 14, 2000.

Time: 7:00 p.m. to 10:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Alec S. Liacouras, PhD,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5154,

MSC 7842, Bethesda, MD 20892, (301) 435–

1740.

(Catalogue of Federal Domestic Assistance

Program nos. 93.,306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333,

93.337, 93.393–93.396, 93.837–93.844,

93.846–93.878, 93.892, 93.893, National

Institutes of Health, HHS)

Dated: May 24, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–13723 Filed 5–31–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: ‘‘Antitumor Macrocyclic

Lactones, Compositions and Methods

of Use’’ and ‘‘Vacuolar-Type (H+)-

ATPase-Inhibiting Compounds,

Compositions, and Uses Thereof’’

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. § 209 (c) (1) and 37 CFR

§ 404.7 (a) (1) (i), that the National

Institutes of Health, Department of

Health and Human Services, is

contemplating the grant of an exclusive

license to practice the inventions

embodied in U.S. Patent Application

60/053,784 entitled, ‘‘Antitumor

Macrocyclic Lactones, Compositions

and Methods of Use’’ filed on July 25,

1997; U.S. Patent Application 60/

122,953 and 60/169,564 entitled,

‘‘Vacuolar-Type (H+)-ATPase-Inhibiting

Compounds, Compositions, and Uses

Thereof’’ filed on March 5, 1999 and

December 8, 1999 respectively to

BioChem Pharma Inc. of Quebec,

Canada. The patent rights in these

inventions have been assigned to the

United States of America.

The prospective exclusive license

territory will be worldwide and the field

of use may be limited to composition of

antitumor macrocyclic lactones and

their uses as cancer therapeutic in

humans.

DATES: Only written comments and/or

license applications which are received

by the National Institutes of Health on

or before July 31, 2000 will be

considered.

ADDRESSES: Requests for copies of the

patent, inquiries, comments and other

materials relating to the contemplated

exclusive license should be directed to:

Girish C. Barua, Ph.D., Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD. 20852–3804.

Telephone: (301) 496–7056, ext. 263;

Facsimile (301) 402–0220; E-mail

BaruaG@od.nih.gov.

SUPPLEMENTARY INFORMATION: The U.S.

Patent Application 60/053,784 claims a

series of macrocyclic lactones based on

compounds isolated from certain

sponges and tunicates collected from

Western Australia. The U.S. Patent

Applications 60/122,953 and 60/

169,564 describe inventions relating to

vacuolar-type (H+)-ATPase-inhibitory

activity of macrocyclic lactones.

Vacuolar-type ATPases (V-ATPases)

have been described as a universal

proton pump which are important for a

myriad of physiological functions such

as sorting of membrane and organellar

proteins; proinsulin conversion;

neurotransmitter uptake, receptor

recycling, and cellular degradative

processes. Licensee of these inventions

will be required to comport with all

applicable federal and country-ofcollection policies relating to

biodiversity.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

§ 209 and 37 CFR 404.7. The

prospective exclusive license may be

granted unless within sixty (60) days

from the date of this published notice,

the NIH receives written evidence and

argument that establish that the grant of

the license would not be consistent with

the requirements of 35 U.S.C. § 209 and

37 CFR 404.7.

Applications for a license in the field

of use filed in response to this notice

will be treated as objections to the grant

of the contemplated exclusive license.

Comments and objections submitted to

this notice will not be made available

for public inspection and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. § 552.

Dated: May 23, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–13732 Filed 5–31–00; 8:45 am]

BILLING CODE 4140–01–P